Continuing trials of GDNF in Parkinson's disease

Lancet Neurology

Volumn 5, Issue 4, 2006, Pages 285-286

  Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; GENETIC HETEROGENEITY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SHORT SURVEY; TREATMENT OUTCOME;

EID: 33644976376     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70386-6     Document Type: Letter

References (6)

1. CB Hurelbrink, RA Barker The potential of GDNF as a treatment for Parkinson's disease Exp Neurol 185 2004 1 6
2. JG Nutt, KJ Burchiel, CL Comella Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73
3. S Love, P Plaha, NK Patel, GR Hotton, DJ Brooks, SS Gill Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain Nat Med 11 2005 703 704
4. SS Gill, NK Patel, GR Hotton Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 9 2003 589 595
5. AE Lang, S Gill, NK Patel Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann Neurol 59 2006 459 466
6. T Foltynie, CE Brayne, TW Robbins, RA Barker The cognitive ability of an incident cohort of Parkinson's patients in the UK: the CamPaIGN study Brain 127 2004 550 560